Patrys's SC1 boosts 10-year survival in gastric cancer

Patrys’s (ASX:PAB) anticancer antibody PAT-SC1 improved 10-year survival rates in patients with gastric cancer during a turn-of-the-century trial.

Ten-year follow-up data from a trial conducted between 1997 and 2001 has been published in the Oncology Reports scientific journal.

The trial evaluated the effectiveness of a single 20 mg dose of PAT-SC1 administered before gastric cancer patients underwent standard surgery, including either subtotal or total gastrectomy with bursectomy, omentectomy and a modified D2-lymphadenectomy.

The results show that survival at 10-year follow-up was significantly higher for PAT-SC1 treated patients, as compared to a historical control group of patients undergoing gastric resection but not the PAT-SC1 injection.

PAT-SC1 was also shown to be well tolerated in all treated patients, with no significant adverse side effects reported.

Previously published data from the trial shows that 81.6% of patients receiving PAT-SC1 demonstrated signs of increased apoptosis within the primary tumour and 60% showed signs of tumour cell regression.

The report’s senior author, Dr Stephanie Brandlein, said the evidence of cancer cell death is encouraging.

“These results are very exciting as this is the first time that a monoclonal IgM antibody like PAT-SC1 has been administered to [patients undergoing radical resection] and the first time that an antibody treatment has resulted in a significant survival benefit,” she said.

Patrys (ASX:PAB) said it is currently seeking an outlicensing partner for PAT-SC1. The company’s shares were trading 6.52% higher at $0.049 as of around 1 pm on Wednesday.